Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NY-ESO-1 Positive”

24 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 24 results

Testing effectiveness (Phase 2)Ended earlyNCT03515551
What this trial is testing

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Who this might be right for
Select Advanced Solid Tumors
Immunocore Ltd 29
Early research (Phase 1)Ended earlyNCT03168438
What this trial is testing

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Who this might be right for
Neoplasms
GlaxoSmithKline 6
Early research (Phase 1)Ended earlyNCT05943990
What this trial is testing

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Who this might be right for
Neoplasms
Adaptimmune 5
Large-scale testing (Phase 3)Looking for participantsNCT07174427
What this trial is testing

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Who this might be right for
Synovial Sarcomas
Takara Bio Inc. 5
Early research (Phase 1)Looking for participantsNCT05881525
What this trial is testing

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
TCRCure Biopharma Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT02992743
What this trial is testing

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Who this might be right for
Neoplasms
GlaxoSmithKline 23
Early research (Phase 1)Study completedNCT01522820
What this trial is testing

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Who this might be right for
Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma+62 more
Roswell Park Cancer Institute 18
Testing effectiveness (Phase 2)Ended earlyNCT05549921
What this trial is testing

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Who this might be right for
Soft Tissue Sarcoma
Sun Yat-sen University 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT05993299
What this trial is testing

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Who this might be right for
Neoplasms
USWM, LLC (dba US WorldMeds) 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT03967223
What this trial is testing

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Who this might be right for
Neoplasms
USWM CT, LLC 103
Early research (Phase 1)Looking for participantsNCT06942143
What this trial is testing

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

Who this might be right for
SarcomaLung CancersMelanoma
Guangzhou FineImmune Biotechnology Co., LTD. 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT06703346
What this trial is testing

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Who this might be right for
Neoplasms
USWM CT, LLC 87
Testing effectiveness (Phase 2)WithdrawnNCT03697824
What this trial is testing

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Who this might be right for
Neoplasms
GlaxoSmithKline
Early research (Phase 1)Ended earlyNCT03240861
What this trial is testing

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Who this might be right for
HLA-A*0201 Positive Cells PresentLocally Advanced Malignant NeoplasmNY-ESO-1 Positive+2 more
Jonsson Comprehensive Cancer Center 5
Early research (Phase 1)Looking for participantsNCT05989828
What this trial is testing

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
University of Southern California 20
Very early researchEnded earlyNCT02774291
What this trial is testing

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Who this might be right for
HLA-A2 Positive Cells PresentMetastatic Malignant NeoplasmMetastatic Malignant Neoplasm in the Brain
Albert Einstein College of Medicine 3
Early research (Phase 1)UnknownNCT04318964
What this trial is testing

TAEST16001 in the Treatment of Soft Tissue Sarcoma

Who this might be right for
Soft Tissue Sarcoma
Sun Yat-sen University 12
Early research (Phase 1)Study completedNCT02588612
What this trial is testing

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Neoplasms
GlaxoSmithKline 10
Early research (Phase 1)Study completedNCT03450122
What this trial is testing

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Who this might be right for
HLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Myxoid Liposarcoma+1 more
M.D. Anderson Cancer Center 15
Early research (Phase 1)WithdrawnNCT03506802
What this trial is testing

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Who this might be right for
HLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Plasma Cell Myeloma+1 more
Jonsson Comprehensive Cancer Center
Load More Results